{"schema_version":"secwatch.filing_event.v1","accession":"0001720580-26-000049","form_type":"8-K","ticker":"ACET","cik":"0001720580","company_name":"Adicet Bio, Inc.","filed_at":"2026-08-05T20:18:14+00:00","discovered_at":"2026-08-05T20:19:02.170553+00:00","generated_at":"2026-08-05T20:19:23.084081+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Adicet Bio Q2 net loss $21.4M; prula-cel Phase 1 update expected 3Q2026 with 22 LN/SLE patients","bullets":["Q2 2026 net loss $21.4M ($1.99/share); cash $118.2M sufficient into 2H2027.","Phase 1 prula-cel update in 3Q2026: 22 LN/SLE patients with ≥6 months follow-up, 13 with ≥12 months.","FDA alignment on potential pivotal trial design for LN; start-up activities planned 2H2026.","Regulatory filing for ADI-212 in mCRPC expected 3Q2026; Phase 1 enrollment anticipated 4Q2026.","Lloyd Klickstein appointed Interim CMO following departure of Dr. Julie Maltzman."],"urls":{"canonical":"https://secwatch.observer/filing/0001720580-26-000049","json":"https://secwatch.observer/filing/0001720580-26-000049.json","markdown":"https://secwatch.observer/filing/0001720580-26-000049.md","text":"https://secwatch.observer/filing/0001720580-26-000049.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720580/000172058026000049/0001720580-26-000049-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720580/000172058026000049/acet-20260805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-05T20:19:23.084081+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}